SAGE Open Medical Case ReportsDespite advancements in the treatment of diffuse large B-cell lymphoma, including CAR T-cell therapy, TP53 mutations remain a significant negative prognostic factor in patients with relapsed/refractory diffuse large B-cell lymphoma.
Ziyi Cai +4 more
doaj +1 more source
Clinicopathological features of extranodal lymphomas: Kuwait experience [PDF]
, 2004 A total of 935 patients with extranodal non-Hodgkin lymphoma (NHL) diagnosed in the period between January 1985 and December 2000 in Kuwait Cancer Center, serving the whole population of Kuwait, were used to describe the clinicopathological and ...
Bamanikar S +17 more
core +1 more source
Variations in “rescuability” of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development [PDF]
, 2004 Idiotypic (Id) vaccination has shown promising results in patients with follicular lymphoma (FL). However, it still remains unclear whether the same approach might be suitable for the treatment of other B-cell malignancies.
Bendandi, M. (Maurizio) +5 more
core +1 more source
Haematologica, 2015 Hepatitis C virus has been found to be associated with B-cell non-Hodgkin lymphomas, mostly marginal zone lymphomas and diffuse large B-cell lymphoma. Deregulation of signaling pathways involved in normal marginal zone development (NOTCH pathway, NF-κB ...
Luca Arcaini +23 more
doaj +1 more source
Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study [PDF]
, 2017 Background: Relapsed or refractory diffuse large B-cell and mantle-cell lymphoma have a poor prognosis. The EPOCH regimen and rituximab monotherapy have demonstrated activity as salvage therapies.
Betticher, D. C. +8 more
core
Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma. [PDF]
, 2016 UNLABELLED: We describe the rationale and design of the ongoing randomized, active-controlled, multicenter, Phase III study evaluating the efficacy of pixantrone and rituximab versus gemcitabine and rituximab in patients with diffuse large B-cell ...
Coiffier B +16 more
core +1 more source
Aortic aneurysm and non-Hodgkin’s lymphoma in Marfan syndrome [PDF]
, 2009 The combination of Marfan syndrome with lymphoma is extremely rare. This report describes a case of Marfan syndrome who presented with chest discomfort and was diagnosed to have an aortic aneurysm and an additional incidental mediastinal mass that on ...
Sandip Kumar Ghosh +2 more
core
Diffuse large B-cell lymphoma, not otherwise specified of the palate: a case report [PDF]
, 2013 Diffuse large B-cell lymphoma (DLBCL) is the most frequent type of non-Hodgkin´s lymphoma found in oral and maxillofacial regions. A large number of cases may be biologically heterogeneous, which are commonly defined as DLBCL, not otherwise specified ...
Castro, Alexandre Fonseca de +3 more
core +1 more source
Atypical burkitt's lymphoma transforming from follicular lymphoma [PDF]
, 2011 Amongst follicular lymphoma that transforms into a high-grade lymphoma, majority are diffuse large B cell lymphoma. Here we reported a rare atypical Burkitt's lymphoma transformation from an asymptomatic follicular lymphoma.
Yu Y Hwang +3 more
core +3 more sources
A Case of a Rapidly Progressive Small Bowel Lymphoma with High Ki-67 Expression
The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2017 Primary intestinal lymphoma is a rare disease. It accounts for approximately 1∼4% of gastrointestinal malignancy. Extranodal lymphoma of the intestine mainly arises from B cells.
Jiyeon Yoo +7 more
doaj +1 more source